GALD Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GALD from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 112.54 |
| 52 Week High | CHF 119.60 |
| 52 Week Low | CHF 60.00 |
| Beta | 0 |
| 1 Month Change | 2.93% |
| 3 Month Change | 31.87% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 75.84% |
Recent News & Updates
Shareholder Returns
| GALD | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -2.7% | 0.2% | 1.9% |
| 1Y | n/a | 19.6% | 10.8% |
Return vs Industry: Insufficient data to determine how GALD performed against the Swiss Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how GALD performed against the Swiss Market.
Price Volatility
| GALD volatility | |
|---|---|
| GALD Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 2.9% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 8.0% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: GALD has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: GALD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,545 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| GALD fundamental statistics | |
|---|---|
| Market cap | CHF 26.74b |
| Earnings (TTM) | -CHF 12.78m |
| Revenue (TTM) | CHF 3.88b |
6.9x
P/S Ratio-2,093x
P/E RatioIs GALD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALD income statement (TTM) | |
|---|---|
| Revenue | US$4.32b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$3.00b |
| Other Expenses | US$3.02b |
| Earnings | -US$14.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 06, 2025
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 69.54% |
| Net Profit Margin | -0.33% |
| Debt/Equity Ratio | 37.1% |
How did GALD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 09:44 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galderma Group AG is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bethan Davies | Berenberg |
| Richard Parkes | BNP Paribas Exane |
| Joffrey Meller | BofA Global Research |